EIF4E inhibitors and uses thereof
The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof. Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with eIF4E. Such diseases, disorders, or conditions include cellular proliferative disorders (e.g., cancer) such as those described herein.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
L 1 is a bond, O, or S;
R 1 is phenyl substituted with 1-4 substituents independently selected from —CN, halogen, —OH, unsubstituted —C 1-6 alkyl, unsubstituted —O—C 1-6 alkyl, and an unsubstituted 3-8 membered monocyclic saturated or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
L 2 is a C 1-8 bivalent straight or branched hydrocarbon chain, wherein 1, 2, or 3 methylene units of the hydrocarbon chain are optionally and independently replaced with —N(R)— or —Cy—;
each R is independently selected from hydrogen or optionally substituted —C 1-6 aliphatic;
each —Cy— is independently an optionally substituted bivalent ring selected from a 3-6 membered monocyclic, saturated or partially unsaturated, carbocyclic ring, or a 3-6 membered monocyclic, saturated or partially unsaturated, heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R 2 is —COOR; and
R 3 is optionally substituted —C 1-6 aliphatic, halogen, or an optionally substituted ring selected from phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1 is a bond.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1 is O.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 2 is a C 1-8 bivalent straight or branched hydrocarbon chain, wherein 1 methylene unit of the hydrocarbon chain is optionally replaced with —N(R)— or —Cy—.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each —Cy— is independently a bivalent C 3-6 monocyclic saturated carbocyclic ring optionally substituted 1-4 times with unsubstituted —C 1-6 alkyl.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each —Cy— is independently a bivalent 3-6 membered monocyclic saturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 1-4 times with unsubstituted —C 1-6 alkyl.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 2 is
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is —COOH.
10. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
L 1 is a bond, O, or S;
R 1 is an optionally substituted ring selected from phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
L 2 is a C 1-8 bivalent straight or branched hydrocarbon chain, wherein 1, 2, or 3 methylene units of the hydrocarbon chain are optionally and independently replaced with —N(R)— or —Cy—;
each R is independently selected from hydrogen or optionally substituted —C I 0.6 aliphatic;
each —Cy— is independently an optionally substituted bivalent ring selected from a 3-6 membered monocyclic, saturated or partially unsaturated, carbocyclic ring, or a 3-6 membered monocyclic, saturated or partially unsaturated, heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
R 2 is —COOR; and
R 3 is optionally substituted phenyl.
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is an optionally substituted 5-6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
12. The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein R 3 is
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
14. The compound of claim 13 , or a pharmaceutically acceptable salt thereof, wherein R 3 is
15. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
16. A compound selected from:
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein R 1 is an unsubstituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
18. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein L 2 is a C 1-8 bivalent straight or branched hydrocarbon chain, wherein 1 methylene unit of the hydrocarbon chain is optionally replaced with —N(R)— or —Cy—.
19. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein each —Cy— is independently a bivalent 3-6 membered monocyclic saturated heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 1-4 times with unsubstituted —C 1-6 alkyl.